HVSEN BIOTECH(300871)2024-10-30 10:42Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 792.55 million yuan, a year-on-year increase of 14.63% [1] - The net profit attributable to shareholders was -47.66 million yuan, a year-on-year decrease of 420.34% [1] - In Q3 2024, the company reported operating revenue of 356.25 million yuan, a year-on-year increase of 47.03% and a quarter-on-quarter increase of 55.46% [1] - The net profit attributable to shareholders in Q3 was 4.22 million yuan, a year-on-year increase of 513.52%, marking a turnaround from losses [1] Cost and Investment - Financial expenses increased by 140.51% year-on-year, primarily due to interest expenses from convertible bonds [2] - R&D expenses for the first three quarters amounted to 38.95 million yuan, a year-on-year increase of 24.82% [2] Product and Market Insights - The sales of conventional formulations have seen rapid growth since Q2, while high-value-added products have shown slower recovery [2] - The production capacity utilization rate for raw material projects reached 90% by the end of Q3, with ongoing improvements in production costs [2] - The prices of raw materials have started to rise since late September, driven by increased demand in the aquaculture industry [2] Market Outlook - The improvement in cash flow within the aquaculture industry is expected to positively impact the animal health sector [3] - The company anticipates that the growth in operating revenue will continue into Q4, supported by favorable market conditions [3]